Gliatech guilty plea
This article was originally published in The Gray Sheet
Executive SummaryAdcon-L developer faces up to $1.2 mil. in fines and a five-year probation under an agreement with the Justice Department. Gliatech pleads guilty to six misdemeanors, including failure to submit Medical Device Reports to FDA, adulteration of a medical device, and the submission of false reports to FDA. The agency currently is reviewing the company's Application Integrity Policy (AIP) corrective action plan (CAP), which was submitted in November 2001. The anti-adhesion product was taken off the U.S. market in January 2001 and is only available internationally...
You may also be interested in...
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
How do the EU’s new MDR cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?
Bio-Thera, which has just started selling China’s first adalimumab biosimilar rival to AbbVie’s top-selling arthritis treatment Humira, has raised $241m in an IPO on the Shanghai Stock Exchange.